Stop CMV Act of 2025
- Sponsor
- Rep. Lawler, Michael [R-NY-17]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 17, 2025
Bottom line
The Stop CMV Act of 2025 aims to establish a nationwide framework for early detection and comprehensive support for congenital Cytomegalovirus through screening, data, education, and research initiatives.
What it actually does
This bill amends the Public Health Service Act to authorize hospitals to screen newborns (21 days or less) for congenital Cytomegalovirus (CMV). It directs states to establish standards for testing, tracking, and information dissemination, with federal oversight from the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children. The bill also authorizes grants for states to administer tests, for the CDC to improve data collection and public education, and for the NIH to expand research into screening, diagnostics, prevention, and treatments for CMV.
Proponents argue
Supporters argue that early detection of congenital CMV is crucial for timely intervention, which can significantly improve health outcomes for affected infants and reduce the severity of long-term disabilities such as hearing loss and developmental delays. They emphasize that a coordinated national effort, including research and public awareness, is essential to combat a condition that is often undetected but can have profound impacts on children's lives.
Opponents contend
Critics might raise concerns about the potential for increased healthcare costs associated with widespread screening, the possibility of false positive results leading to unnecessary parental anxiety and further diagnostic procedures, and the resource allocation implications for states and healthcare systems already facing budget constraints. Some may also question the federal government's role in mandating or incentivizing state-level health screening programs.
The bill is very short and clearly written, making it highly accessible for any reader to understand its provisions and implications within a few minutes.
Section 2, inserting new Section 1116A(a) into the Public Health Service Act.
Authorization for Congenital Cytomegalovirus Screening
This provision authorizes hospitals and other healthcare entities caring for infants 21 days old or less to administer tests for congenital Cytomegalovirus (CMV). It establishes the foundational permission for widespread screening of this condition in newborns.
Supporters argue
Supporters argue that authorizing universal or near-universal screening for congenital CMV is a critical step to identify affected infants early, allowing for interventions that can mitigate severe long-term health consequences like hearing loss and developmental delays.
Critics contend
Critics might express concerns about the logistical challenges and costs for hospitals to implement new screening programs, especially if not fully funded, and the potential for false positives to create undue stress for families.
Tradeoffs
This provision balances the public health benefit of early detection against the operational burdens and potential for increased parental anxiety associated with widespread screening.
Section 2, inserting new Section 1116A(b) into the Public Health Service Act.
State Standards and Federal Oversight for CMV Screening
This section allows states to set their own standards and procedures for CMV testing, including recording results, tracking, follow-up, and educational activities. Importantly, if a state fails to establish approved standards within two years, the federal Discretionary Advisory Committee on Heritable Disorders in Newborns and Children will prescribe them. All state standards are subject to review and approval by this Advisory Committee.
Section 2, inserting new Section 1116A(c) into the Public Health Service Act.
Federal Funding for CMV Initiatives
This provision authorizes federal grants across three agencies. The Health Resources and Services Administration (HRSA) can award grants to states for administering CMV tests. The Centers for Disease Control and Prevention (CDC) can provide grants for states to develop data collection systems and educate healthcare providers and the public. The National Institutes of Health (NIH) is directed to establish or expand research programs on new screening techniques, intervention efficacy, diagnostics, prevention, treatments, and vaccine development for congenital Cytomegalovirus.
Specifies that congenital Cytomegalovirus screening is authorized for infants who are "21 days or less of age."
Section 2, new Section 1116A(a)
Why it matters:This is standard legislative practice to define the scope and applicability of a program with specific parameters, rather than an attempt to obscure.
Case for: Proponents would argue that this specific age limit is based on medical evidence regarding the optimal window for detecting congenital CMV and initiating early interventions, ensuring the screening is effective and timely.
Case against: No strong case against this specific detail, though some might argue for flexibility or a slightly different window based on evolving medical understanding, but this is a minor point.
Estimated impact: Ensures that screening efforts are focused on the most critical period for congenital CMV detection, maximizing the potential for positive health outcomes for a specific cohort of infants.
If a state does not prescribe and get approval for its CMV screening standards within two years of the Act's enactment, the federal Discretionary Advisory Committee on Heritable Disorders in Newborns and Children shall prescribe appropriate standards for that state.
Section 2, new Section 1116A(b)(3)
Why it matters:This is a common legislative technique to ensure implementation and prevent inaction by states, rather than an attempt to be evasive. It provides a mechanism for federal oversight without an immediate mandate.
Case for: Supporters would argue this provision is crucial for ensuring that all states eventually implement CMV screening programs, preventing a patchwork of inconsistent or absent screening, and upholding a national public health standard.
Case against: Critics might view this as a subtle federal mandate, potentially infringing on state sovereignty in public health matters, especially if states believe the federal standards are not suitable for their specific contexts or resources.
Estimated impact: Guarantees eventual nationwide implementation of CMV screening standards, even if some states are initially reluctant or slow to act, thereby broadening the reach of the program.